Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > The BTD thing
View:
Post by Oilminerdeluxe on Nov 30, 2021 1:16am

The BTD thing

So, when might this be given realistically?
Comment by robertshaw on Nov 30, 2021 1:22am
maybe 2 months later, we will get it.only God knows...
Comment by Oilminerdeluxe on Nov 30, 2021 1:33am
Do we need like 25 patients done at 15 months or so was what my feeble mind was supposed to write. Or can the BTD be given at any time? I suspect this has been debated but I can't rememeber what was said then. I have to say I feel very happy about this. Relieved and very hopeful about the future. Financings should not be a problem going forward. (Better unjinx that one). This simply must be ...more  
Comment by CancerSlayer on Nov 30, 2021 2:29am
Last post all imo. Hey oilminer...if the optimized CR rates continue to look good in the 7 pending patients, I think a BTD app could be filed.  There is no need to wait for durable/360+ day data on any specific or minimum number of optimized patients....as BTDs are generally awarded based on a primary/clinically significant endpoint (I.e. CR rate).  All imo.
Comment by Oilminerdeluxe on Nov 30, 2021 3:25am
CancerSlayer, thank you. Looking good. After all these years. Some nice positive momentum.
Comment by Rumpl3StiltSkin on Nov 30, 2021 9:29am
All I have to add to this topic, is that from my reading and understanding, FT or BT, either one will lead to Accelerated Approval(commercialization) IF the durable CR data supports it after the 450days or so that the FDA has specd for TLT. Like Slayer said BT designation could be an upgrade to the current FT if the 90day CR %s continue at this rate, or improve. That could happen any time, I ...more  
Comment by Pandora on Nov 30, 2021 2:35am
Posted this a couple of days ago but will run it through again -- maybe it does not answer any questions: Info only - picked up off another board: - breakthrough therapy designation is requested by the drug company. If a sponsor has not yet requested breakthrough therapy designation, FDA may suggest that the sponsor consider submitting a request if (1) after reviewing submitted data and ...more  
Comment by Oilminerdeluxe on Nov 30, 2021 3:26am
Thanks Pandora.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250